Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BOLT
$5.02
$
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Next Earnings
2026-02-25
Beta
0.916
Average Volume
Market Cap
Last Dividend
CIK
0001641281
ISIN
US0977022039
CUSIP
097702203
CEO
William Quinn
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
52
IPO Date
2021-02-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Bolt Biotherapeutics to Participate in Upcoming March Conferences | REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: | GlobeNewsWire | 2026-02-24 08:00:00 |
| Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 83.8% in December | Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 352 shares, a decrease of 83.8% from the December 15th total of 2,177 shares. Approximately 0.0% of the shares of the company are sold short. Based | Defense World | 2026-01-14 04:58:55 |
| Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) | Acumen Pharmaceuticals (NASDAQ: ABOS - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Earnings and Valuation This table compares Acumen | Defense World | 2025-12-15 02:08:49 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13D/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-10-24 | 2025-10-24 | View Filing |
| 4 | 2025-10-24 | 2025-10-24 | View Filing |
| 4 | 2025-10-24 | 2025-10-24 | View Filing |
| 8-K | 2025-10-02 | 2025-10-02 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-04 | 2025-06-04 | View Filing |
| 8-K | 2025-05-28 | 2025-05-27 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-16 | 2025-04-16 | View Filing |
| PRE 14A | 2025-04-16 | 2025-04-15 | View Filing |
| DEF 14A | 2025-04-15 | 2025-04-15 | View Filing |
| S-8 | 2025-03-24 | 2025-03-24 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-01-03 | 2025-01-03 | View Filing |
| 8-K | 2024-12-23 | 2024-12-23 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-09-06 | 2024-09-06 | View Filing |
| 3 | 2024-09-06 | 2024-09-06 | View Filing |
| 8-K | 2024-09-04 | 2024-09-04 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-07-24 | 2024-07-24 | View Filing |
| 4 | 2024-07-24 | 2024-07-24 | View Filing |
| 4 | 2024-07-24 | 2024-07-24 | View Filing |
| 8-K | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-06-14 | 2024-06-14 | View Filing |
| 8-K | 2024-06-14 | 2024-06-14 | View Filing |
| DEFA14A | 2024-05-20 | 2024-05-20 | View Filing |
| 3 | 2024-05-15 | 2024-05-15 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| S-8 | 2024-03-21 | 2024-03-21 | View Filing |
| 10-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 4 | 2024-03-06 | 2024-03-06 | View Filing |
| 4 | 2024-03-06 | 2024-03-06 | View Filing |
| 4 | 2024-03-06 | 2024-03-06 | View Filing |
| 4 | 2024-03-06 | 2024-03-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 48.32% | 0.99 | 253 | 0.07 | 0.13 | 50.03 |
| Bollinger Bands Strategy | 46.10% | 0.96 | 43 | 0.06 | 0.12 | 47.82 |
| Larry Williams PercentR Strategy | 38.72% | 0.99 | 165 | 0.06 | 0.12 | 40.43 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxx | xxxxx |
| xxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxx | xxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |